GlycoMimetics Priced, Nasdaq: GLYC
Clinical-stage biotech developing treatments for sickle cell episodes and AML.
Industry: Health Care
First Day Return: +12.6%
Industry: Health Care
GLYC
Clinical-stage biotech developing treatments for sickle cell episodes and AML.
| IPO Data | |
|---|---|
| IPO File Date | 10/04/2013 |
| Offer Price | $8.00 |
| Price Range $8.00 - $8.00 | |
| Offer Shares (mm) | 7.0 |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 01/09/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Gaithersburg, MD, United States |
| Founded | 2003 |
| Employees at IPO | 28 |
| Website www.glycomimetics.com | |
IPO News for GlycoMimetics
GlycoMimetics (GLYC) Performance
